Hemab Therapeutics Holdings Inc
COAG
NASDAQ
Biotechnology
$54.94
USD
+0.99 (+1.84%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.33B
Volume 101.2K
Revenue
—
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
—
TTM
— YoY
Operating Cash Flow
—
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2026 |
|---|---|
Revenue | 0.0 |
YoY Growth | — |
Cost of Revenue | 0.0 |
Gross Profit | 0.0 |
Selling, General & Administrative | 5.7 |
Other Operating Expenses | 0.0 |
Total Operating Expenses | 26.1 |
Operating Income | -26.1 |
EBITDA | -26.0 |
Other Income / Expense | -0.8 |
Total Other Income / Expense | 2.0 |
Income Before Income Taxes | -24.1 |
Income Taxes | 0.1 |
Net Income | -24.2 |
Consolidated Net Income / Loss | -24.2 |
Net Income Attributable to Common Shareholders | -24.2 |
Basic EPS | -$0.80 |
Diluted EPS | -$0.80 |
Basic Shares Outstanding | 30.1M |
Diluted Shares Outstanding | 30.1M |